The global deep brain stimulation devices for Parkinson’s disease market is estimated to reach USD 135.6 Billion by 2021, growing at a CAGR of 7.2% from 2017 to 2021.
Browse Deep Brain Stimulation Devices for Parkinson’s Disease Market by Geography North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Rest of the World, and Forecast 2016-2020 at https://www.ihealthcareanalyst.com/report/deep-brain-stimulation-devices-parkinsons-disease-market/
Deep brain stimulation (DBS) delivers electrical pulses to brain cells to decrease symptoms of Parkinson’s disease (PD), especially if symptoms cannot be adequately controlled with medication. The electrical signals delivered by DBS de-activate the target site within the brain without destroying any tissue, restoring the balance of electrical activity within brain, to offset the progressive loss of cells caused by Parkinson’s. Older surgical therapies such as pallidotomy and thalamotomy can ease symptoms but have not been proven to change the underlying course of disease. Deep brain stimulation improves levodopa-responsive symptoms, dyskinesia, and tremor, where benefits are long-lasting in many motor domains. DBS uses a surgically implanted, battery-operated medical device called an implantable pulse generator (IPG) to deliver electrical stimulation to specific areas in the brain that control movement, thus blocking the abnormal nerve signals that cause PD symptoms. Advances in the understanding of DBS mechanisms and improvements in the devices and surgical approaches are underway for a wider variety of people at different stages of Parkinson’s. Since its approval by the Food and Drug Administration for PD in 2002, more than 70,000 patients have undergone DBS surgery, according to Medtronic Inc.
The global deep brain stimulation devices for Parkinson’s disease market report estimates the market size (Revenue USD million – 2013 to 2020) by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World and forecasts growth trends (CAGR% – 2016 to 2020). The global deep brain stimulation devices for Parkinson’s disease market report also provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments.
Major players operating the global deep brain stimulation devices for Parkinson’s disease market and profiled in this report include Aleva Neurotherapeutics, Boston Scientific Corporation, Medtronic Inc., and St. Jude Medical Inc.
To request Table of Contents and Sample Pages of this report visit: https://www.ihealthcareanalyst.com/report/deep-brain-stimulation-devices-parkinsons-disease-market/
iHealthcareAnalyst, Inc. is a global healthcare market research and consulting company providing market analysis, and competitive intelligence services to global clients. The company publishes syndicate, custom and consulting grade healthcare reports covering animal healthcare, biotechnology, clinical diagnostics, healthcare informatics, healthcare services, medical devices, medical equipment, and pharmaceuticals.
In addition to multi-client studies, we offer creative consulting services and conduct proprietary single-client assignments targeted at client’s specific business objectives, information needs, time frame and budget. Please contact us to receive a proposal for a proprietary single-client study.
2109, Mckelvey Hill Drive,
Maryland Heights, MO 63043
Email: [email protected]